Investigational drug · Phase 3
Pegozafermin
Also called: BIO89-100
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "Pegozafermin"
First trial start
2023
Jun 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pegozafermin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Severe Hypertriglyceridemia
Approved drugs for the same conditions: High triglycerides · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Pegozafermin" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06419374 · 1,800 participants (planned) · Start May 24, 2024 · Primary completion Jun 30, 2028
Drug: Pegozafermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Sites: Birmingham, Alabama; Homewood, Alabama; Chandler, Arizona · 335 sites in all
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06318169 · 1,350 participants (planned) · Start Mar 13, 2024 · Primary completion Feb 2029
Drug: Pegozafermin · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 370 sites in all
- To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe HypertriglyceridemiaPivotal-lookingCompleted
89bio, Inc.Industry
NCT05852431 · 369 participants · Start Jun 15, 2023 · Primary completion Jul 7, 2025
Drug: Pegozafermin; Placebo · For: Severe Hypertriglyceridemia
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 177 sites in all
- Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
89bio, Inc.Industry
NCT04929483 · 222 participants · Start Jun 4, 2021 · Primary completion Feb 14, 2023
Drug: BIO89-100; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Guntersville, Alabama · 89 sites in all
- A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy ParticipantsPivotal-lookingNot yet recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07835243 · 105 participants (planned) · Start Nov 5, 2026 · Primary completion Mar 2, 2027
Drug: Pegozafermin · For: Healthy Volunteers
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHPivotal-lookingCompleted
89bio, Inc.Industry
NCT04048135 · 101 participants · Start Jul 29, 2019 · Primary completion Aug 28, 2020
Drug: Pegozafermin · For: NASH
Sites: Madison, Alabama; Chandler, Arizona; Tucson, Arizona · 26 sites in all
89bio, Inc.Industry
NCT04541186 · 86 participants · Start Sep 1, 2020 · Primary completion May 19, 2022
Drug: Pegozafermin; Placebo · For: Severe Hypertriglyceridemia
Sites: La Mesa, California; San Francisco, California; Clearwater, Florida · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The use of FGF21 analogues in MASH and MASH cirrhosis - metabolic master regulators or liver-specific mechanisms?
Holleboom AG, Schattenberg JM · JHEP Rep 2026
- Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis.
Loomba R, Daniel PCN, Wang Y, et al. · Clin Gastroenterol Hepatol 2026
- Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.
Loomba R, Chen R, Wang Y, et al. · Hepatology 2026
- MASLD: Established Knowledge and Emerging Directions - Guideline Updates.
Roeb E, Geier A · Z Gastroenterol 2026
- Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives.
Tamehri Zadeh SS, Toth PP, Banach M · Front Pharmacol 2026
- Current and Emerging Pharmacological Therapies for Hypertriglyceridemia.
Alhomoud IS · Int J Mol Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.